Key Metrics VCs Look For in Pre-Revenue Health Tech Startups

Investors prioritize startups with a clearly defined strategy for FDA clearance or CE marking, including the chosen classification (510(k), De Novo, or PMA) and a realistic timeline for approval. This demonstrates technical feasibility and reduces regulatory risk.

A robust, defensible intellectual property portfolio is critical, including granted patents or strong pending applications that protect core algorithms, hardware designs, or proprietary data structures. Strong IP prevents competitor entry and increases exit valuation.

Even without revenue, preliminary clinical data, pilot study results, or proof-of-concept trials that demonstrate clinical efficacy or improved workflow efficiency are essential. This evidence bridges the gap between theoretical benefit and real-world application.

A high-caliber advisory board featuring respected physicians, regulatory experts, and industry veterans signals credibility and provides access to networks. VCs view this as a substitute for early customer traction by validating market needs.

Non-binding Letters of Intent from prospective hospital systems, payers, or distributors indicate genuine market interest and potential future revenue streams. While not guarantees, they reduce perceived market risk for early-stage investors.

A clear plan for CPT codes, HCPCS coding, or value-based care integration is vital. Investors need to see that there is a viable path for healthcare providers and insurers to pay for the solution once deployed.

A large, well-defined TAM demonstrates the potential for significant returns. Investors look for startups targeting high-cost, high-volume conditions where health tech can deliver measurable efficiency gains or cost reductions.

Evidence that the technology can scale beyond initial pilot sites without proportional cost increases, such as cloud-based infrastructure or automated data processing. This ensures the business model supports rapid growth post-regulatory approval.

Demonstrated adherence to HIPAA, GDPR, and SOC 2 standards is non-negotiable in health tech. Startups must show that data governance and patient privacy are built into the architecture, not added as an afterthought.

Founders with deep domain expertise in healthcare, such as former clinicians or regulatory specialists, are highly valued. This expertise reduces execution risk and builds trust with potential clinical partners and investors.

Qualitative feedback from early clinical users indicating that the tool improves workflow or reduces administrative burden. Positive UX insights suggest high adoption rates once the product reaches broader markets.

Data from small-scale deployments with key accounts that show engagement metrics, error reduction, or time savings. These tangible results provide concrete evidence of product-market fit before commercial launch.

A clear articulation of how the technology outperforms existing standards of care or incumbent solutions, whether through superior accuracy, lower cost, or faster results. Unique value propositions drive investor confidence in market capture.

Existing or proposed partnerships with larger health systems, pharma companies, or device manufacturers can de-risk the commercialization phase. These alliances often provide distribution channels and additional funding resources.

A disciplined approach to capital allocation that extends runway to key milestones like regulatory submission or pivotal trial completion. Efficient use of funds signals operational maturity and respect for investor capital.

Support for HL7 FHIR or other interoperability standards ensures seamless integration into existing Electronic Health Record (EHR) systems. This reduces implementation friction for hospitals and accelerates adoption cycles.

For AI-driven health tech, transparent model development, bias mitigation strategies, and explainable AI frameworks are increasingly scrutinized. Strong ethical governance mitigates reputational and legal risks associated with algorithmic decisions.

A detailed plan for navigating formulary approvals, payer negotiations, and procurement processes specific to the healthcare industry. Understanding these barriers is crucial for projecting realistic commercial timelines.

A track record of successfully bringing products from concept to market in regulated environments. Past successes in navigating complex healthcare ecosystems are strong predictors of future performance.

A clear path to recurring revenue through SaaS subscriptions, licensing fees, or per-test pricing rather than one-time hardware sales. Recurring models offer higher valuations and more predictable cash flows for investors.